BRUSSELS and CHICAGO, June 23 /CNW/ - The International Diabetes
Federation (IDF) today called for projects that adapt science to meet the
needs of people living with diabetes and to implement practical solutions for
improving diabetes care and prevention worldwide. The programme, known as
BRIDGES (Bringing Research in Diabetes to Global Environments and Systems),
was announced at the 19th World Diabetes Congress in Cape Town, South Africa
and was officially launched today at the 67th Scientific Sessions of the
American Diabetes Association.
The IDF BRIDGES grant programme will fund translational research projects
in diabetes. Proposals should support cost effective and sustainable
strategies that can be adopted in real world settings, for the prevention and
control of diabetes. The BRIDGES grant programme is funded through an
educational grant from Eli Lilly and Company.
"Although there have been tremendous advances in science, particularly
through landmark clinical trials, diabetes still continues to rise, and the
related morbidity and mortality have not been reduced. Translational research
is needed to identify practical strategies that can improve the lives of
people living with diabetes," said Professor Jean-Claude Mbanya,
President-elect of IDF.
An example of translational research in diabetes is taking proven
lifestyle interventions found effective through trials and training groups not
usually considered to be devoted to healthcare (religious groups, teachers,
employees) on healthy living. For example, the Diabetes Prevention Program
(DPP) was a multi-site project implemented throughout the United States whose
findings demonstrated that lifestyle intervention was effective in reducing
the risk for diabetes in people with pre-diabetes. In Pittsburgh,
Pennsylvania, a translational research project is being facilitated where
people in urban communities with high risk for diabetes are using the DPP
lifestyle interventions and doing prevention programmes in their churches and
wellness centres. Thus far, the programme has been highly effective and
provided the opportunity to reach underserved and at-risk communities and to
"Unfortunately there are not always opportunities to translate the
science from ivory tower academic institutions into real world communities,"
said Dr Linda Siminerio, Executive Director of the University of Pittsburgh
Diabetes Institute and former IDF Senior Vice-President. "Through
translational research and with the help of key community members, we begin to
learn how to effectively champion healthy lifestyles, and improve our ability
to prevent diabetes and its complications."
"In many cases we have the scientific knowledge and proven therapies,
however we need to adapt this knowledge to meet the needs of our communities.
BRIDGES is the perfect vehicle to do this and I would encourage all health
professionals and researchers to join us and to channel their expertise to
improving the lives of people living with diabetes."
Through BRIDGES, IDF will provide funding for pilot projects and outcome
studies over the course of seven years. Relevant topics include methods and
strategies to improve health care delivery to people with/at risk of diabetes;
enhance diabetes self management; promote healthy lifestyles or lifestyle
change to reduce the risk of diabetes; and identify people with pre-diabetes
and undiagnosed diabetes in cost effective ways.
"Lilly is committed to delivering breakthrough pharmaceutical products
that improve the lives of people with diabetes," said Jose Caro, MD, Vice
President of Global Diabetes Care Outcomes, Eli Lilly and Company. "Still, we
know that success won't come through medical intervention alone. We believe
BRIDGES will identify important new ways to help people with diabetes meet the
challenges they face every day and we are excited about this next step."
The BRIDGES Review Committee, a multi-disciplinary committee managed by
IDF will consider cost effectiveness, sustainability and the ability of
interventions to be widely replicated in other settings. They will encourage
projects targeting high risk groups and underserved populations.
The application form is available at www.idfbridges.org. Deadline for
application is 2 November 2007. Grantees will be selected and announced in
early December 2007.
Note to Editors:
The International Diabetes Federation (IDF) is the global advocate for
more than 240 million people with diabetes worldwide. It represents 200
diabetes associations in more than 160 countries. Its mission is to promote
diabetes care, prevention and a cure worldwide. IDF is an NGO in official
relations with the World Health Organization and an associated NGO with the
United Nations Department of Public Information. Additional information about
IDF is available at www.idf.org.
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs. Additional
information about Lilly is available at www.lilly.com.
For further information:
For further information: Kerrita McClaughlyn at ADA, email@example.com,
mobile: +32-487-530625 or Anne Pierson, firstname.lastname@example.org, at IDF Brussels office